- Service Name
iLet Bionic Pancreas
- Industry
Medical Technology, Diabetes Management
- Main Value Proposition
Fully automated insulin delivery system that reduces the need for manual decision-making in diabetes management
- Description
The iLet Bionic Pancreas is a revolutionary insulin delivery system that works with the Dexcom G6 or G7 CGM to make diabetes management easier and more efficient.
- Key Features
Fully automated insulin delivery, works with Dexcom G6 or G7 CGM, reduces need for manual decision-making
- Use Cases
The iLet Bionic Pancreas can be used by people with type 1 diabetes, ages 6 and up.
- Competitive advantages
The iLet Bionic Pancreas is the first and only fully automated insulin delivery system on the market.
- Pricing
N/A
- Strengths
Revolutionary technology, reduces need for manual decision-making, works with popular CGM systems
- Positioning
The iLet Bionic Pancreas is positioned as a game-changing technology in the field of diabetes management.
- Audience
The iLet Bionic Pancreas is targeted towards people with type 1 diabetes, ages 6 and up.
- CTA
Get Started, Upgrade now
- Social Proof
Nationwide launch, added to national commercial formularies, secured $100 million in funding, appointed Chief Medical Officer
- Tone of Voice
Innovative, efficient, life-changing
- Trust Factors
FDA clearance, clinical trial results, public benefit corporation
- Differentiation
The iLet Bionic Pancreas is the first and only fully automated insulin delivery system on the market.
- Brand Positioning
Beta Bionics, the company behind the iLet Bionic Pancreas, is committed to balancing purpose with profit and giving back to society.
- Founded
2015-10-21
- Founders
Ed Damiano
Sean Saint
Toby Milgrome